Ulrich BEUERS
JHEP Rep. 2022;4:100573. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice. Kunst RF, de Waart DR, Wolters F, Duijst S, Vogels EW, Bolt I, Verheij J, Beuers U, Oude Elferink RPJ, van de Graaf SFJ. PubMed
Liver Int. 2020;40:3042-3050. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. de Vries E, Mazzetti M, Takkenberg B, Mostafavi N, Bikker H, Marzioni M, de Veer R, van A, der Meer, Doukas M, Verheij J, Beuers U. PubMed
J Hepatol. 2019;71:153-162. Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice. Aronson SJ, Bakker RS, Shi X, Duijst S, Ten Bloemendaal L, de Waart DR, Verheij J, Elferink RPO, Beuers U, Paulusma CC, Bosma PJ. PubMed
Nucl Med Commun. 2019;40:388-392. Stress test of liver function using technetium-99m-mebrofenin hepatobiliary scintigraphy. Rassam F, Cieslak KP, Beuers UHW, van Gulik TM, Bennink RJ. PubMed
HPB (Oxford). 2018;In press. Scintigraphic liver function and transient elastography in the assessment of patients with resectable hepatocellular carcinoma. Rassam F, Olthof PB, Takkenberg BR, Beuers U, Klümpen HJ, Bennink RJ, van Lienden KP, Besselink MG, Busch OR, Verheij J, van Gulik TM. PubMed
Hepatology. 2018;68;1057-1069. Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice.Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. PubMed
Lancet. 2018;391:2547-2559. Primary sclerosing cholangitis. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. PubMed
Sci Rep. 2017;7:15307. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Donkers JM, Zehnder B, van Westen GJP, Kwakkenbos MJ, IJzerman AP, Oude Elferink RPJ, Beuers U, Urban S, van de Graaf SFJ. PubMed
Hepatology. 2017;66:1631-1643. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S, de Waart DR, Tolenaars D, van der Meer JHM, Wildenberg M, Beuers U, Oude Elferink RPJ, Schinkel AH, van de Graaf SFJ. PubMed
J Hepatol. 2017;67:145-172. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. European Association for the Study of the Liver. PubMed
Gastroenterology. 2017;152:1975-1984. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chaouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. PubMed
Liver Int. 2017;37:1554-1561. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-center study. de Vries EM, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. PubMed
Dig Dis. 2017;35:217-223. The emerging role of soluble adenylyl cyclase in primary biliary cholangitis. Chang JC, Beuers U, Oude Elferink RP. PubMed
Lancet. 2017:389:1114-1123. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. PubMed
Lancet. 2017;389:709-717. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. PubMed
Hepatology. 2017; in press. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice. Maroni L, Hohenester SD, van de Graaf SF, Tolenaars D, van Lienden K, Verheij J, Marzioni M, Karlsen TH, Oude Elferink RP, Beuers U. PubMed
Liver Int. 2017;37:S123-S129. Management of cholestatic disease in 2017. de Vries E, Beuers U. PubMed
J Hepatol. 2015;62:S25-37. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. Beuers U, Trauner M, Jansen P, Poupon R. PubMed
Hepatology. 2015;62:207-19. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice. Slijepcevic D, Kaufman C, Wichers CG, Gilglioni EH, Lempp FA, Duijst S, de Waart DR, Elferink RP, Mier W, Stieger B Beuers U, Urban S, van de Graaf SF. PubMed
Clin Rev Allergy Immunol. 2015;48:243-53. Gene replacement therapy for genetic hepatocellular jaundice. van Dijk R, Beuers U, Bosma PJ. PubMed
Liver Int. 2015;35:1478-88. Characterization and treatment of persistent hepatocellular secretory failure. van Dijk R, Kremer AE, Smit W, van den Elzen B, van Gulik T, Gouma D, Lameris JS, Bikker H, Enemuo V, Stokkers PC, Feist M, Bosma P, Jansen PL, Beuers U. PubMed
Curr Opin Gastroenterol. 2012;28:253-7. The biliary HCO(3)(-) umbrella: experimental evidence revisited. Beuers U, Maroni L, Elferink RO. PubMed
Hepatology. 2012;55:173-83. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. PubMed
Expert Opin Ther Targets. 2011;15:1173-82.Targeting the ABCB4 gene to control cholesterol homeostasis. Oude Elferink RP, Beuers U. PubMed
Dig Dis. 2011;29:62-5. Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man.Hohenester S, Maillette de Buy Wenniger L, Jefferson DM, Oude Elferink RP, Beuers U. PubMed
Curr Drug Targets. 2011;12:661-70.The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Stieger B, Beuers U. PubMed
Hepatology. 2010;52:1489-96. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. PubMed
J Hepatol. 2008;49:881-3. New light on anion exchangers in primary biliary cirrhosis. Beuers U, Oude-Elferink RP. PubMed
Pharmacogenet Genomics. 2007;17:47-60. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed
Nat Clin Pract Gastroenterol Hepatol. 2006;3:318-28.Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Beuers U. PubMed